Related references
Note: Only part of the references are listed.
Article
Immunology
Gabriel Chodick et al.
Summary: The study evaluated the real-world effectiveness of the BNT162b2 vaccine in Israel, showing a significantly reduced incidence of infection during the protection period compared to the reference period. The vaccine demonstrated 90% effectiveness in preventing infection and 94% effectiveness against COVID-19, with lower efficacy observed in immunosuppressed elderly individuals.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Chantal Williams et al.
Summary: In a COVID-19 outbreak in a long-term care home, the effectiveness of the vaccine against SARS-CoV-2 infection was 52.5% in residents and 66.2% in staff members. The vaccine demonstrated 78.6% effectiveness against severe illness in residents. However, two vaccinated residents still died during the outbreak.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Danuta M. Skowronski et al.
Summary: Vaccine effectiveness estimated in British Columbia, Canada showed that one dose of mRNA vaccine reduced the risk of SARS-CoV-2 infection in adults >= 70 years old by about two-thirds, with protection only minimally reduced against Alpha and Gamma variants.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Cardiac & Cardiovascular Systems
Yael Peled et al.
Summary: This study investigated the safety and immunogenicity of a third dose of the Pfizer BNT162b2 vaccine in heart transplant patients. The results showed that the third dose had a low rate of adverse events and elicited a strong immune response.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2022)
Article
Health Care Sciences & Services
B. Quiroga et al.
Summary: The majority of Spanish nephrologists have received Covid-19 vaccines, with common side effects including local reactions, myalgia, tiredness, and headache. Age and prior Covid-19 infection were predictors of vaccination side effects.
JOURNAL OF HEALTHCARE QUALITY RESEARCH
(2021)
News Item
Multidisciplinary Sciences
Ewen Callaway
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
[Anonymous]
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Julianne Gee et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Letter
Rheumatology
Caoilfhionn M. Connolly et al.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Immunology
Melanie D. Swift et al.
Summary: In a large cohort of US healthcare personnel without prior COVID-19 infection, 94,382 doses of mRNA vaccines were administered to 49,220 individuals, with an adjusted vaccine effectiveness exceeding 96% following 2 doses of mRNA vaccine.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Mei-Xian Zhang et al.
Summary: The study aimed to assess the safety of the CoronaVac vaccine among healthcare workers, finding a low incidence of adverse reactions with localized pain at the injection site being the most common, indicating an acceptable safety profile for the vaccine among this population.
EXPERT REVIEW OF VACCINES
(2021)
Article
Public, Environmental & Occupational Health
Anne M. Hause et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Medicine, General & Internal
Yoel Angel et al.
Summary: This cohort study in Tel Aviv, Israel, found that vaccination with the Pfizer-BioNTech BNT162b2 vaccine was significantly associated with a lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection among health care workers more than 7 days after the second dose.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Editorial Material
Biochemistry & Molecular Biology
Rong Li et al.
JOURNAL OF GENETICS AND GENOMICS
(2021)
Article
Cardiac & Cardiovascular Systems
Yael Peled et al.
Summary: The study investigated the safety and efficacy of BNT162b2 vaccine in heart transplant recipients, showing a low rate of adverse events and some individuals developing antibody responses. The presence of IgG anti-RBD antibodies was associated with neutralizing SARS-CoV-2 pseudo-virus, but certain immunosuppressive regimens may impact the odds of an antibody response. Further research is needed to determine the optimal observation period for antibody response in immunocompromised individuals.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2021)
Article
Gastroenterology & Hepatology
Jitao Wang et al.
Summary: The study demonstrates that COVID-19 vaccination is safe and immunogenic in patients with non-alcoholic fatty liver disease (NAFLD). Most adverse reactions post-vaccination are mild and transient.
JOURNAL OF HEPATOLOGY
(2021)
Article
Immunology
Francesco Paolo Bianchi et al.
Summary: The study evaluated the effectiveness of the BNT162b2 mRNA vaccine against documented infection among healthcare workers from Bari Policlinico University Hospital, showing high effectiveness levels after vaccination. Concerns remain about unvaccinated healthcare workers during the pandemic emergency.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Tom T. Shimabukuro et al.
Summary: Preliminary data indicates that there are no obvious safety signals among pregnant women who received mRNA Covid-19 vaccines, but more data is needed for further confirmation. Adverse reactions such as injection-site pain were reported more frequently in pregnant women, but most pregnancies resulted in live births with some cases of preterm birth and small size for gestational age.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Jamie Lopez Bernal et al.
Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Editorial Material
Medicine, General & Internal
Dominic Pimenta et al.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Public, Environmental & Occupational Health
David K. Shay et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Public, Environmental & Occupational Health
Tamara Pilishvili et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Public, Environmental & Occupational Health
Mark W. Tenforde et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Public, Environmental & Occupational Health
Amadea Britton et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Public, Environmental & Occupational Health
Alyson M. Cavanaugh et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Review
Immunology
Ali Pormohammad et al.
Summary: This study systematically reviewed the clinical features of COVID-19 vaccines in clinical trials, finding that mRNA-based and adenovirus-vectored vaccines exhibited different efficacy and side effect profiles. Both types of vaccines showed high efficacy after the first and second doses, with mRNA-based vaccines having higher reported side effects.
Article
Medicine, General & Internal
Gang Lv et al.
Summary: The mortality rate of COVID-19 vaccination was 8.2 per million population, with a higher rate among residents in long-term care facilities. Reported comorbidities associated with deaths included hypertension, dementia, COPD, diabetes, and heart failure. Dementia was more likely to be associated with deaths among those vaccinated at long-term care facilities compared to other locations.
FRONTIERS IN MEDICINE
(2021)
Article
Rheumatology
Victoria Furer et al.
Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Oncology
Gabriel Revon-Riviere et al.
Summary: The study evaluated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with solid tumors, showing good tolerability and effectiveness in preventing COVID-19 infection in this population. Additional monitoring is needed to confirm these preliminary results and determine long-term vaccination effectiveness.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Gastroenterology & Hepatology
Nabeel Khan et al.
Summary: The study found that full vaccination against SARS-CoV-2 has an effectiveness of approximately 80.4% in patients with inflammatory bowel disease who may be taking immunosuppressive medications.
Article
Public, Environmental & Occupational Health
Pablo Knobel et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2021)
Review
Virology
Yunzhi Ling et al.
Summary: The study found that the incidence of adverse reactions of SARS-CoV-2 vaccines currently undergoing clinical trials is high, with common adverse reactions being pain, swelling, and fever at the injection site. From the perspective of effectiveness and safety, RNA vaccines perform the best among the three types of vaccines.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Letter
Public, Environmental & Occupational Health
Takanao Hashimoto et al.
JOURNAL OF TRAVEL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Sara Reardon
Article
Biochemistry & Molecular Biology
Hiam Chemaitelly et al.
Summary: A study showed that the mRNA-1273 vaccine is highly effective against the B.1.1.7 and B.1.351 variants of concern, with efficacy rates of 100% and 96.4% respectively. The vaccine's effectiveness increases rapidly in the weeks following the first dose, reaching maximum efficacy after the second dose, providing strong protection against severe COVID-19 outcomes.
Article
Medicine, General & Internal
Alejandro Jara et al.
Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Lawrence Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Mark G. Thompson et al.
Summary: The study demonstrated that COVID-19 mRNA vaccines were highly effective in preventing SARS-CoV-2 infection in real-world conditions, while also attenuating the viral RNA load, febrile symptoms, and illness duration among vaccinated individuals who had breakthrough infections.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
H. M. El Sahly et al.
Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
A. Vallee et al.
Summary: A study conducted in Foch Hospital, France, on 451 healthcare workers who received the AstraZeneca vaccine found that 60.8% reported multiple adverse effects, with fever, fatigue, and muscle pain being the main symptoms. Despite some European countries temporarily suspending the vaccine due to safety concerns, the benefit of vaccination remains evident.
Article
Rheumatology
Somy Cherian et al.
Summary: The study found that there were no significant differences in adverse reaction rates between patients with autoimmune rheumatic diseases (AIRD) and non-AIRD after receiving the ChAdOx1 or BBV152 vaccines, confirming the safety of the vaccines in rheumatic and musculoskeletal diseases (RMDs).
RHEUMATOLOGY INTERNATIONAL
(2021)
Article
Acoustics
S. Bookstein Peretz et al.
Summary: This observational study compared the immunogenicity and reactogenicity of the Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine between pregnant and non-pregnant women. The study found that pregnant women experienced similar rates of adverse effects following vaccination as non-pregnant women, with lower levels of SARS-CoV-2 IgG. The vaccine was effective in generating a humoral immune response in pregnant women, with no safety concerns identified.
ULTRASOUND IN OBSTETRICS & GYNECOLOGY
(2021)
Article
Immunology
Aurelie Baldolli et al.
Summary: The study found that individuals with a history of COVID-19 infection are more likely to experience systemic reactions and symptoms like fatigue, headache, and fever after receiving the BNT162b2 mRNA Covid-19 vaccine. Although these individuals had higher severity of reactions, overall tolerance was good.
Article
Multidisciplinary Sciences
Tariq Azamgarhi et al.
Summary: This study examined the uptake and effectiveness of the BNT162B2 vaccine among UK healthcare workers during a period of high COVID-19 prevalence. The early uptake rate was relatively high, but there were differences in uptake among different groups. Partial vaccination was associated with a significant reduction in the risk of COVID-19 infection.
NATURE COMMUNICATIONS
(2021)
Editorial Material
Biotechnology & Applied Microbiology
Javier Burgos-Salcedo
Summary: The study found that the JANSSEN vaccine had the highest score among the COVID-19 vaccines studied. However, the analysis suggests that the WHO criteria could be more useful if considered separately, while also taking into account the social, demographic, and economic characteristics of each country.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Review
Infectious Diseases
Musha Chen et al.
Summary: A systematic review and meta-analysis found that the safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported adverse events following immunization (AEFI). Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions.
INFECTIOUS DISEASES OF POVERTY
(2021)
Article
Immunology
Chia Siang Kow et al.
Summary: This study summarized the overall vaccine effectiveness of the BNT162b2 mRNA vaccine through meta-analyses, finding significant protective effects against COVID-19 confirmed by RT-PCR ≥14 days after the first dose and ≥7 days after the second dose.
INFLAMMOPHARMACOLOGY
(2021)
Letter
Allergy
Yossi Rosman et al.
Summary: Patients with mast cell disorders can safely receive the BNT162b2 mRNA COVID-19 vaccine without the need for specific measures.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Oncology
Tal Goshen-Lago et al.
Summary: This study aimed to evaluate the safety of BNT162b2 vaccine in patients undergoing cancer treatment. The results showed most cancer patients achieved seroconversion after the second dose of the vaccine, but at a slower rate compared to non-cancer controls. Future real-world data are needed to determine the long-term efficacy of the vaccine in different types of cancer treatments.
Article
Medicine, General & Internal
Abanoub Riad et al.
Summary: COVID-19 vaccine hesitancy poses a serious threat to achieving community immunity through mass vaccination. Independent studies on vaccine side effects can help boost public confidence and uptake. A study in Turkish healthcare workers found a higher prevalence of CoronaVac side effects compared to clinical trials, with factors like gender and health status potentially impacting the risk of side effects.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Galia Zacay et al.
Summary: A real-world observational study found that vaccination with the BNT162b2 vaccine has an effectiveness of 89% in preventing SARS-CoV-2 infection. Among individuals who underwent frequent PCR testing, the vaccination significantly reduced the positive test rate after receiving two doses of the vaccine.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Immunology
Abdulaziz Alhazmi et al.
Summary: A study conducted in Saudi Arabia found that side effects reported after receiving Oxford-AstraZeneca and Pfizer-BioNTech vaccines are similar to those reported in clinical trials, indicating the safety of these vaccines. Most participants reported fatigue and pain at the injection site as common side effects. Further research is needed to assess the effectiveness of these vaccines in protecting against SARS-CoV-2 reinfections.
Article
Immunology
Abanoub Riad et al.
Summary: This study investigated the prevalence of side effects following AstraZeneca COVID-19 vaccine among healthcare workers in Germany and Czech Republic. The majority of participants reported experiencing at least one side effect, with common symptoms including injection site pain, fatigue, and muscle pain. Most side effects resolved within 1-3 days, with younger age groups being less affected and slightly higher frequencies observed in females and participants previously infected with COVID-19. Further independent studies are needed to evaluate vaccine safety and explore potential factors influencing side effects.
Article
Immunology
Maria Elena Flacco et al.
Summary: This study compared the rates of COVID-19 infections among vaccinated and unvaccinated residents in an Italian province, finding that vaccination was highly effective in preventing infections, symptomatic or lethal COVID-19, with an effectiveness exceeding 95%. There were no differences in effectiveness observed across genders, and even among those who received the second dose later than recommended.
Article
Medicine, General & Internal
Gabriel Chodick et al.
Summary: The short-term effectiveness of the first dose of the BNT162b2 vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting was assessed, showing comparable results to the phase III randomized clinical trial.
Article
Health Care Sciences & Services
Rosario Barranco et al.
Summary: The global spread of SARS-CoV-2 and the resulting pandemic have raised serious challenges in the medical, legal, and ethical fields regarding vaccination. Healthcare professionals play a crucial role in promoting the importance of vaccination, providing comprehensive information and relying on scientific research to build trust among the public. From both criminal and civil law perspectives, it is important to balance the protection of healthcare workers and the public, ensuring the safety and effectiveness of vaccinations.
Article
Hematology
Ron Ram et al.
Summary: In this prospective evaluation, the BNT162b2 mRNA COVID-19 vaccine showed good tolerability and impressive immunogenicity in patients after allogeneic HCT or CART. While most adverse events were mild and transient, some significant hematologic events were observed, indicating the need for close monitoring of patients.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Medicine, Research & Experimental
Reid McMurry et al.
Summary: This study analyzed over 1.2 million EHR notes and found that individuals vaccinated with BNT162b2 or mRNA-1273 had a higher rate of return to the clinic after both doses with no increase in emergency department visits. Common adverse effects within seven days post-vaccination included myalgia, headache, and fatigue, while severe events occurred at similar frequencies in vaccinated and unvaccinated individuals.
Article
Medicine, Research & Experimental
Colin Pawlowski et al.
Summary: The study analyzed the effectiveness of BNT162b2 and mRNA-1273 vaccines in preventing COVID-19 in a real-world setting, and found that both vaccines were highly effective in reducing SARS-CoV-2 infection rates and lowering the burden of COVID-19 on the healthcare system.
Article
Public, Environmental & Occupational Health
Brijesh Sathian et al.
Summary: The study evaluates the safety and immunogenicity of COVID-19 vaccine candidates and the implementation of mass immunization. Despite advanced techniques for rapid vaccine development in emergency situations, production and availability of an effective vaccine may still take some time.
NEPAL JOURNAL OF EPIDEMIOLOGY
(2021)
Letter
Medicine, General & Internal
Bina Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
